- Home
- HGBL vs PRLD Comparison
HGBL vs PRLD Comparison
Compare HGBL & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HGBL
- PRLD
- Stock Information
- Founded
- HGBL 1937
- PRLD 2016
- Country
- HGBL United States
- PRLD United States
- Employees
- HGBL N/A
- PRLD N/A
- Industry
- HGBL Business Services
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- HGBL Consumer Discretionary
- PRLD Health Care
- Exchange
- HGBL Nasdaq
- PRLD Nasdaq
- Market Cap
- HGBL 72.0M
- PRLD 73.7M
- IPO Year
- HGBL N/A
- PRLD 2020
- Fundamental
- Price
- HGBL $2.03
- PRLD $1.05
- Analyst Decision
- HGBL
- PRLD Strong Buy
- Analyst Count
- HGBL 0
- PRLD 2
- Target Price
- HGBL N/A
- PRLD $4.50
- AVG Volume (30 Days)
- HGBL 101.9K
- PRLD 611.2K
- Earning Date
- HGBL 03-13-2025
- PRLD 02-13-2025
- Dividend Yield
- HGBL N/A
- PRLD N/A
- EPS Growth
- HGBL N/A
- PRLD N/A
- EPS
- HGBL 0.27
- PRLD N/A
- Revenue
- HGBL $49,878,000.00
- PRLD $3,000,000.00
- Revenue This Year
- HGBL N/A
- PRLD N/A
- Revenue Next Year
- HGBL $19.47
- PRLD N/A
- P/E Ratio
- HGBL $7.50
- PRLD N/A
- Revenue Growth
- HGBL N/A
- PRLD N/A
- 52 Week Low
- HGBL $1.52
- PRLD $0.80
- 52 Week High
- HGBL $3.09
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- HGBL 70.20
- PRLD 45.27
- Support Level
- HGBL $1.92
- PRLD $0.98
- Resistance Level
- HGBL $2.12
- PRLD $1.43
- Average True Range (ATR)
- HGBL 0.09
- PRLD 0.12
- MACD
- HGBL 0.02
- PRLD -0.02
- Stochastic Oscillator
- HGBL 79.07
- PRLD 14.14
About HGBL Heritage Global Inc.
Heritage Global Inc values and monetizes industrial and financial assets by providing acquisition, disposition, valuation, and lending services for surplus and distressed assets. It aids in facilitating the economy by diverting useful industrial assets from landfills and operating a supply chain by overseeing the post-sale account activity of financial assets. The group operates in four segments namely Auction and Liquidation; Refurbishment and Resale; Brokerage and Specialty Lending. It generates maximum revenue from the Auction and Liquidation segment. The Auction and Liquidation segment, through HGP, operates as a global full-service auction, appraisal, and asset advisory firm, including the acquisition of turnkey manufacturing facilities and used industrial machinery and equipment.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.